NCT03804996View on ClinicalTrials.gov

Study of TG-1801 in Subjects With B-Cell Lymphoma

PHASE1CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

March 5, 2019

Primary Completion Date

February 21, 2024

Study Completion Date

February 21, 2024

Conditions
B-Cell Lymphoma
Interventions
DRUG

TG-1801

Intravenous infusion over 1 hour every 4 weeks

BIOLOGICAL

Ublituximab

"recombinant chimeric anti-CD20 monoclonal antibody, available in 25 mg/mL administered as an IV infusion once every 4 weeks"

Trial Locations (3)

03084

TG Therapeutics Investigational Trial Site, Heidelberg

Unknown

TG Therapeutics Investigational Trial Site, Melbourne

06009

TG Therapeutics Investigational Trial Site, Nedlands

All Listed Sponsors
lead

TG Therapeutics, Inc.

INDUSTRY

NCT03804996 - Study of TG-1801 in Subjects With B-Cell Lymphoma | Biotech Hunter | Biotech Hunter